Cancer-Related Pain Clinical Trial
Official title:
The Effectiveness of Progressive Muscle Relaxation Technique in Reducing Cancer-related Pain Among Palliative Care Patients: A Randomized Controlled Trial
Verified date | June 2020 |
Source | University of Jordan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized controlled trial was designed to evaluate the effectiveness of the
Progressive Muscle Relaxation (PMR) technique in reducing Cancer-related Pain (CRP) in
patients receiving palliative care in Jordan.
The main hypothesis (H0) of this trial is that cancer patients receiving palliative care do
not report a decrease in pain intensity levels and an improve in pain interferences with life
activities as a result of participating in PMR technique to a significant extent compared to
patients who do not participate. The sub-hypothesis (H1) of this trial is that cancer
patients receiving palliative care report a decrease in pain intensity levels and an improve
in pain interferences with life activities as a result of participating in PMR technique to a
significant extent compared to patients who do not participate.
Status | Completed |
Enrollment | 148 |
Est. completion date | December 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - age of 18 years and older - diagnosed with cancer. - reported complaints of pain =1 on a 0-10 Numerical Rating Scale (NRS) in the 24 hours before recruitment. - were treated with non-opioid or weak opioid analgesic. - had a Karnofsky Performance Scale Index = 20. - had regular access to a telephone. Exclusion Criteria: - a diagnosis of psychiatric illness, central nervous system tumors and musculoskeletal disorders (because these conditions may limit the effectiveness of PMR technique). - using any type of complementary therapy during the trial period. - Patients who had no pain and were treated with strong opioid analgesics. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Jordan |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cancer-related pain | Brief Pain Inventory (BPI) was used to assess cancer-related pain. The BPI consists of two subscales: (1) pain intensity, and (2) pain interferences with life activities. The pain intensity is evaluated at 4 different times: (1) the worst pain in the last 24 hours, (2) the least pain in the last 24 hours, (3) pain on average, and (4) pain right now. By asking patients to rate their pain on the 0 (no pain) to 10 (pain as bad as you can imagine) rating scale, the average of these 4 items is the person's pain intensity. The second subscale, pain interference, consists of 7 items that evaluate the extent to which pain interferes with general activity, walking, mood, relations with others, working, sleep, and enjoyment of life. Each item is rated on the 0 (does not interfere) to 10 (completely interferes). | The BPI assessment was collected at baseline (T0) ( pre-intervention) | |
Primary | Cancer-related pain | Brief Pain Inventory (BPI) was used to assess cancer-related pain. The BPI consists of two subscales: (1) pain intensity, and (2) pain interferences with life activities. The pain intensity is evaluated at 4 different times: (1) the worst pain in the last 24 hours, (2) the least pain in the last 24 hours, (3) pain on average, and (4) pain right now. By asking patients to rate their pain on the 0 (no pain) to 10 (pain as bad as you can imagine) rating scale, the average of these 4 items is the person's pain intensity. The second subscale, pain interference, consists of 7 items that evaluate the extent to which pain interferes with general activity, walking, mood, relations with others, working, sleep, and enjoyment of life. Each item is rated on the 0 (does not interfere) to 10 (completely interferes). | The BPI assessment was collected at the end of PMR technique (4 weeks from T0) | |
Primary | Cancer-related pain | Brief Pain Inventory (BPI) was used to assess cancer-related pain. The BPI consists of two subscales: (1) pain intensity, and (2) pain interferences with life activities. The pain intensity is evaluated at 4 different times: (1) the worst pain in the last 24 hours, (2) the least pain in the last 24 hours, (3) pain on average, and (4) pain right now. By asking patients to rate their pain on the 0 (no pain) to 10 (pain as bad as you can imagine) rating scale, the average of these 4 items is the person's pain intensity. The second subscale, pain interference, consists of 7 items that evaluate the extent to which pain interferes with general activity, walking, mood, relations with others, working, sleep, and enjoyment of life. Each item is rated on the 0 (does not interfere) to 10 (completely interferes). | The BPI assessment was collected at 1-month follow-up (T2) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04040140 -
Integrating Auricular Point Acupressure Into Real-world Nursing Practice to Manage Cancer-related Pain
|
N/A | |
Recruiting |
NCT04125953 -
Stochastic Modulated Vibrations on Autonomic Nervous System of Breast Cancer Patients During Radiotherapy
|
N/A | |
Not yet recruiting |
NCT04007861 -
Exploring the Link Between Cancer Genetics and PPSP
|
||
Completed |
NCT01384877 -
Subcutaneous Lidocaine For Cancer-Related Pain
|
Phase 2/Phase 3 | |
Recruiting |
NCT05910190 -
Buprenorphine for Cancer Pain
|
Phase 4 | |
Enrolling by invitation |
NCT04844788 -
A Consensus on Opioid Prescription for Oncologic Patients in Latin America - A DELPHI Study.
|